Novagali Pharma names scientific advisory board

May 1

- Fort Lauderdale, FL - Novagali Pharma, a biopharmaceutical company based in Evry, France, which develops innovative drug delivery systems in ophthalmology, has appointed seven individuals to its scientific advisory board. The company chose experts from America, Japan, Israel, and France.The seven members of the board are:

•Professor Simon Benita (Israel), president of the scientific advisory board and cofounder of Novagali Pharma, professor in the school of pharmacy in Jerusalem, and a specialist in drug delivery, nanotechnology, and emulsion technology.

•Professor Penny Asbell (United States), professor of ophthalmology at Mount Sinai Hospital, New York, director of the cornea service and refractive surgery center, and a specialist in dry eye and refractive surgery.

•Professor Christophe Baudouin (France), professor of ophthalmology at the Quinze-Vingt Hospital, Paris, associate professor of the Inserm U598 laboratory in the University of Paris V, and president of the Ophthalmological Society of Paris.

•Dr. Francine Behar-Cohen (France), retinal surgeon in the department of ophthalmology of Hotel Dieu, Paris, and director of the Inserm U598 laboratory in the University of Paris V.

•Professor Patrick Couvreur (France), professor of pharmacy at the University of Paris XI - Faculty de pharmacy in Chatenay-Malabry, director of the CNRS unit UMR 8612 (a multidisciplinary research group), and a member of the Board of Pharmaceutical Sciences International Federation of Pharmacy.

•Professor José-Alain Sahal (France), head of ophthalmological service at the Quinze-Vingt Hospital, Paris, director of the Inserm U592 laboratory at the Saint-Antoine Hospital, and head of the Institut de la Vision project slated for 2007.

•Professor Kazuo Tsubota (Japan), professor and chairperson, department of ophthalmology, Keio University School of Medicine, Tokyo, and visiting professor, department of ophthalmology, Tokyo Dental College, Chiba.

Novagali Pharma is specialized in cationic emulsions and is developing new therapeutic products for ophthalmic pathologies, such as dry eye syndrome and age-related macular degeneration (AMD).